Lymphocyte populations and their change during five-year glatiramer acetate treatment.
Pavelek, Zbysek; Vysata, Oldrich; Sobísek, Lukás; Klímová, Blanka; Andrýs, Ctirad; Vokurková, Doris; Mazurová, Radka; Stourac, Pavel; Valis, Martin.
Neurol Neurochir Pol
; 52(5): 587-592, 2018.
Artigo em Inglês | MEDLINE | ID: mdl-30190211
Glatiramer Acetate Stimulates Regulatory B Cell Functions.
Pharmacogenetics of multiple sclerosis: personalized therapy with immunomodulatory drugs.
Efficacy and safety of a three-times-weekly dosing regimen of glatiramer acetate in relapsing-remitting multiple sclerosis patients: 3-year results of the Glatiramer Acetate Low-Frequency Administration open-label extension study.
Antibody response to seasonal influenza vaccination in patients with multiple sclerosis receiving immunomodulatory therapy.
Oral contraceptives and MS disease activity in a contemporary real-world cohort.
Switching from branded to generic glatiramer acetate: 15-month GATE trial extension results.
Effect of delayed-release dimethyl fumarate on no evidence of disease activity in relapsing-remitting multiple sclerosis: integrated analysis of the phase III DEFINE and CONFIRM studies.
Risk of early relapse following the switch from injectables to oral agents for multiple sclerosis.
Long-term follow-up of pediatric MS patients starting treatment with injectable first-line agents: A multicentre, Italian, retrospective, observational study.
Avidekel Cannabis extracts and cannabidiol are as efficient as Copaxone in suppressing EAE in SJL/J mice.